Efficacy and Safety of Lebrikizumab Is Maintained to Two Years in Patients With Moderate-to-Severe Atopic Dermatitis. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 Apr. 3];7(6):s271. Available from: https://skin.dermsquared.com/skin/article/view/2382